Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such ...
Migraine is linked to a 30% lower risk for dementia and a 42% lower risk for Alzheimer’s disease than not having migraine, a ...
Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has extended the review period by three months for the supplemental Biologics License ...
A review found obesity and Alzheimer’s disease share metabolic disruptions that may damage brain cells, raising the ...
Advancing the Alector Brain Carrier (ABC) platform across multiple therapeutic modalities, including antibodies, enzymes, and siRNA, with ...
9h
Acumen Pharmaceuticals to Participate in the Bank of America Securities 2026 Health Care Conference
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s ...
Researchers hoped results from the latest trial on low-dose lithium would settle the question of lithium’s potential to ...
Detailed price information for Oncotelic Therapeutcs Inc (OTLC) from The Globe and Mail including charting and trades.
The University of Kansas Medical Center is set to receive $5 million from the state to build the Kansas Brain Health ...
Meeting with FDA Division of Psychiatry scheduled for May 2026 expected to informregistrational plans for zervimesine in DLB psychosis PURCHASE, N.Y., May 07, 2026 (GLOBE NEWSWIRE) -- Cognition ...
KOASTAL-2 and -3 studies evaluating navacaprant in major depressive disorder on track for joint topline readout in the second quarter of 2026 Progressing NMRA-511 in Alzheimer’s disease agitation and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results